Streetbeat News

Regulatory

BNTX

CVAC

GSK

PFE

Acuitas Therapeutics and CureVac NV settled a lawsuit over COVID-19 vaccine patent credits. Acuitas accused CureVac of omitting its scientists from patent applications for lipid nanoparticle technology. This settlement comes amid broader legal battles involving CureVac, Pfizer, BioNTech, and now GSK over mRNA vaccine patents. A German court recently invalidated a CureVac patent central to its case against BioNTech and Pfizer. GSK has also sued Pfizer and BioNTech for patent infringement.

Portfolio Pulse from Vandana Singh

April 26, 2024 | 6:45 pm

BTI

MO

PM

SPY

The U.S. Health Secretary announced that the proposed rule to ban menthol cigarettes will require more time for implementation. This delay affects major tobacco companies and could impact their stock prices in the short term.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 6:38 pm

ALPN

VRTX

Vertex Pharmaceuticals Inc (VRTX) has seen significant success with its cystic fibrosis drug Trikafta, generating $26 billion in revenues since 2019 and expected to reach $10 billion in annual sales next year. The company is now focusing on developing non-opioid painkillers, with VX-548 in late-stage trials and potential FDA approval this year. Vertex also acquired Alpine Immune Sciences Inc (ALPN) for $4.9 billion to develop treatments for autoimmune kidney disease. Analysts predict Vertex's new pain medication could bring in $2.3 billion in annual sales by 2030.

Portfolio Pulse from Vandana Singh

April 26, 2024 | 6:34 pm

CSLLY

PFE

The FDA approved Pfizer Inc's gene therapy, Beqvez, for hemophilia B in adults, offering a one-time treatment alternative to regular intravenous infusions. Beqvez demonstrated significant efficacy in the BENEGENE-2 Phase 3A study, leading to a median annualized bleeding rate of zero. Pfizer has launched a warranty program for Beqvez, priced at $3.5 million in the U.S., and is awaiting approval in Europe while already approved in Canada. Pfizer's stock rose 0.88% to $25.48 following the announcement.

Portfolio Pulse from Vandana Singh

April 26, 2024 | 6:30 pm

BA

Fitch Ratings suggests that Boeing's potential control of Spirit AeroSystems will face near-term financial pressures but benefit from long-term synergies. Boeing is expected to maintain a slower production pace into late May 2024 as it addresses FAA concerns.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 6:30 pm

BTCUSD

Arthur Hayes, BitMEX Co-founder, encourages crypto investors to maintain their conviction in the ongoing bull market, emphasizing the macroeconomic environment of currency debasement as a fundamental reason for the crypto rally. He advocates for a 'Left Curve' mentality of buying and holding cryptocurrencies, highlighting Bitcoin's increasing institutional adoption and potential as a hedge against currency debasement and negative real yields. Hayes predicts further economic stimulus measures ahead of the 2024 U.S. presidential election, bolstering Bitcoin's appeal.

Portfolio Pulse from Khyathi Dalal

April 26, 2024 | 6:15 pm

BTI

SPY

The Biden Administration has decided not to proceed with its previously announced plan to ban menthol cigarettes. This decision marks a significant shift in policy direction, impacting stakeholders in the tobacco industry and potentially affecting market dynamics for related stocks.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 6:03 pm

LYB

LyondellBasell Industries plans to exit its Houston refinery business, recording liabilities of $262M as of March 31, 2024. The estimated asset retirement obligations for the Houston refinery range from $150M to $450M, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 6:02 pm

SPY

Former President Trump announced on Truth Social his willingness to debate President Biden 'ANYWHERE, ANYTIME, ANYPLACE,' signaling potential political volatility.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 5:40 pm

SPY

The U.S. Bureau of Labor Statistics announced a correction to a computation error in the hours worked and labor productivity data for the years 2019-2023. This correction could impact interpretations of labor market efficiency and productivity trends over the period.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 5:36 pm